Journal of Medical Economics, Volume 15, Issue 2 (2012)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Journal of Medical Economics, Volume 15, Issue 2 (2012)

See all volumes and issues
Vol 27, 2024 Vol 26, 2023 Vol 25, 2022 Vol 24, 2021 Vol 23, 2020 Vol 22, 2019 Vol 21, 2018 Vol 20, 2017 Vol 19, 2016 Vol 18, 2015 Vol 17, 2014 Vol 16, 2013 Volume 15, 2012 Vol 14, 2011 Vol 13, 2010 Vol 12, 2009 Vol 11, 2008 Vol 10, 2007 Vol 9, 2006 Vol 8, 2005 Vol 7, 2004 Vol 6, 2003 Vol 5, 2002 Vol 4, 2001 Vol 3, 2000 Vol 2, 1999 Vol 1, 1998
Download citations Download PDFs Download issue

Original Article

Article
A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain
Jason Gordon, Steven Lister, Matthew Prettyjohns, Phil McEwan, Anthony Tetlow & Zahava Gabriel
Pages: 207-218
Published online: 17 Nov 2011
AbstractforA cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain | Full Text | References | PDF (255.2 KB)
  • 969 Views
  • 17 CrossRef citations
  • 0Altmetric
Free Access
Article
Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis
Sujit S. Sansgiry, Vijay N. Joish, Susan Boklage, Ravi K. Goyal, Pooja Chopra & Sanjay Sethi
Pages: 219-224
Published online: 06 Dec 2011
AbstractforEconomic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis | Full Text | References | PDF (176.2 KB)
  • 1017 Views
  • 15 CrossRef citations
  • 0Altmetric
Free Access
Article
Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective
Elisabeth Luporsi, Lamine Mahi, Camille Morre, Jorge Wernli, Gérard de Pouvourville & Roland Bugat
Pages: 225-232
Published online: 05 Dec 2011
AbstractforEvaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective | Full Text | References | PDF (169.8 KB)
  • 755 Views
  • 11 CrossRef citations
  • 0Altmetric
Free Access
Article
Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico
Fernando Carlos, Jocelyn Ramírez-Gámez, Héctor Dueñas, Rosa María Galindo-Suárez & Elisa Ramos
Pages: 233-244
Published online: 05 Dec 2011
AbstractforEconomic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico | Full Text | References | PDF (429.4 KB)
  • 759 Views
  • 10 CrossRef citations
  • 0Altmetric
Free Access
Article
The burden of chronic low back pain with and without a neuropathic component: a healthcare resource use and cost analysis
Maneesha Mehra, Kala Hill, Deborah Nicholl & Jan Schadrack
Pages: 245-252
Published online: 05 Dec 2011
AbstractforThe burden of chronic low back pain with and without a neuropathic component: a healthcare resource use and cost analysis | Full Text | References | PDF (212.3 KB)
  • 2558 Views
  • 87 CrossRef citations
  • 0Altmetric
Free Access
Article
Cost-effectiveness analysis of valsartan versus losartan and the effect of switching
Timothy M. Baker, Jowern Goh, Atholl Johnston, Heather Falvey, Yvonne Brede & Ruth E. Brown
Pages: 253-260
Published online: 05 Dec 2011
AbstractforCost-effectiveness analysis of valsartan versus losartan and the effect of switching | Full Text | References | PDF (195.1 KB)
  • 2139 Views
  • 4 CrossRef citations
  • 0Altmetric
Free Access

Research letter

Article
Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes
J. Jendle, M. Ridderstråle, O. Torfvitt, Å Ericsson & S. Larsen
Pages: 261-263
Published online: 06 Dec 2011
AbstractforWillingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes | Full Text | References | PDF (68.4 KB)
  • 742 Views
  • 4 CrossRef citations
  • 0Altmetric
Free Access

Original Article

Article
Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States
Vernon F. Schabert, Crystal Watson, Shravanthi R. Gandra, Seth Goodman, Kathleen M. Fox & David J. Harrison
Pages: 264-275
Published online: 08 Dec 2011
AbstractforAnnual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States | Full Text | References | PDF (743.3 KB)
  • 1262 Views
  • 32 CrossRef citations
  • 0Altmetric
Free Access
Article
Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial
Jun R. Chiong, Sonnie Kim, Jay Lin, Rudell Christian & Joseph F. Dasta
Pages: 276-284
Published online: 08 Dec 2011
AbstractforEvaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial | Full Text | References | PDF (147.4 KB)
  • 907 Views
  • 29 CrossRef citations
  • 0Altmetric
Free Access
Article
A cost-effectiveness analysis of reducing ventilator-associated pneumonia at a Danish ICU with ventilator bundle
Anders Holmen Møller, Louise Hansen, Morten Sall Jensen & Lars Holger Ehlers
Pages: 285-292
Published online: 19 Dec 2011
AbstractforA cost-effectiveness analysis of reducing ventilator-associated pneumonia at a Danish ICU with ventilator bundle | Full Text | References | PDF (301.7 KB)
  • 1195 Views
  • 12 CrossRef citations
  • 0Altmetric
Free Access

Research Article

Article
Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis
Huseyin Naci, Gregory de Lissovoy, Christopher Hollenbeak, Brian Custer, Axel Hofmann, William McClellan & Matthew Gitlin
Pages: 293-304
Published online: 16 Dec 2011
AbstractforHistorical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis | Full Text | References | PDF (264.7 KB)
  • 990 Views
  • 7 CrossRef citations
  • 0Altmetric
Free Access

Original Article

Article
Patient/caregiver perceived benefits and barriers to elective orthopedic surgery (EOS) in patients with congenital hemophilia with inhibitors
M. DeKoven, T. Wisniewski, A. Petrilla, N. Holot, W. C. Lee & D. Cooper
Pages: 305-312
Published online: 03 Jan 2012
AbstractforPatient/caregiver perceived benefits and barriers to elective orthopedic surgery (EOS) in patients with congenital hemophilia with inhibitors | Full Text | References | PDF (260.6 KB)
  • 527 Views
  • 4 CrossRef citations
  • 0Altmetric
Free Access
Article
Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue
M. Iskedjian, A. T. Tinmouth, D. M. Arnold, R. Deuson, J. J. Isitt & J. Mikhael
Pages: 313-331
Published online: 03 Jan 2012
AbstractforElicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue | Full Text | References | PDF (650 KB)
  • 513 Views
  • 2 CrossRef citations
  • 0Altmetric
Free Access
Article
Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients
Chureen T. Carter, Arun K. Changolkar & R. Scott McKenzie
Pages: 332-339
Published online: 06 Jan 2012
AbstractforAdalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients | Full Text | References | PDF (146.4 KB)
  • 1136 Views
  • 20 CrossRef citations
  • 0Altmetric
Free Access
Article
Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis
E. J. Soini, T. A. Hallinen, K. Puolakka, V. Vihervaara & M. J. Kauppi
Pages: 340-351
Published online: 06 Jan 2012
AbstractforCost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis | Full Text | References | PDF (404 KB)
  • 2505 Views
  • 38 CrossRef citations
  • 0Altmetric
Free Access
Article
Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings
Marie-Hélène Lafeuille, Robert A. Bailey, Francis Vekeman, R. Scott McKenzie & Patrick Lefebvre
Pages: 352-360
Published online: 09 Jan 2012
AbstractforUtilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings | Full Text | References | PDF (158.5 KB)
  • 671 Views
  • 2 CrossRef citations
  • 0Altmetric
Free Access
Article
Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy
Margarita Udall, James Harnett & Jack Mardekian
Pages: 361-370
Published online: 09 Jan 2012
AbstractforCosts of pregabalin or gabapentin for painful diabetic peripheral neuropathy | Full Text | References | PDF (102.9 KB)
  • 729 Views
  • 12 CrossRef citations
  • 0Altmetric
Free Access
Article
Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies
Chakkarin Burudpakdee, Zhongyun Zhao, Julie Munakata, Sue Gao, Karen Trochlil & Beth Barber
Pages: 371-377
Published online: 16 Jan 2012
AbstractforEconomic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies | Full Text | References | PDF (88.2 KB)
  • 985 Views
  • 14 CrossRef citations
  • 0Altmetric
Free Access
Article
Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children
Michael Iskedjian, Dominique Belli, Bechara Farah, Vincent Navarro & Patrick Detzel
Pages: 378-393
Published online: 17 Jan 2012
AbstractforEconomic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children | Full Text | References | PDF (3.9 MB)
  • 439 Views
  • 7 CrossRef citations
  • 0Altmetric
Free Access
Article
Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Danish children
Michael Iskedjian, Ferdinand Haschke, Bechara Farah, Jenny van Odijk, Jade Berbari & Jörg Spieldenner
Pages: 394-408
Published online: 17 Jan 2012
AbstractforEconomic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Danish children | Full Text | References | PDF (161.1 KB)
  • 447 Views
  • 9 CrossRef citations
  • 0Altmetric
Free Access

Explore articles

Explore the most recently published articles

Impact of Pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis
Meg Franklin et al.
Article | Published online: 27 Apr 2024
Open Access
Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
Karissa Johnston et al.
Article | Published online: 27 Apr 2024
Open Access
Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder
Jeff Schein et al.
Article | Published online: 27 Apr 2024
Open Access
Value-based payment and financing for cell and gene therapies: challenges and potential solutions
James X. Zhang et al.
Editorial | Published online: 27 Apr 2024
Open Access
View all latest articles